Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Magnetic Resonance Imaging | Research article

Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma

Authors: Yong Tang, Chun Mei Yang, Song Su, Wei Jia Wang, Li Ping Fan, Jian Shu

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Radiomics may provide more objective and accurate predictions for extrahepatic cholangiocarcinoma (ECC). In this study, we developed radiomics models based on magnetic resonance imaging (MRI) and machine learning to preoperatively predict differentiation degree (DD) and lymph node metastasis (LNM) of ECC.

Methods

A group of 100 patients diagnosed with ECC was included. The ECC status of all patients was confirmed by pathology. A total of 1200 radiomics features were extracted from axial T1 weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion weighted imaging (DWI), and apparent diffusion coefficient (ADC) images. A systematical framework considering combinations of five feature selection methods and ten machine learning classification algorithms (classifiers) was developed and investigated. The predictive capabilities for DD and LNM were evaluated in terms of area under precision recall curve (AUPRC), area under the receiver operating characteristic (ROC) curve (AUC), negative predictive value (NPV), accuracy (ACC), sensitivity, and specificity. The prediction performance among models was statistically compared using DeLong test.

Results

For DD prediction, the feature selection method joint mutual information (JMI) and Bagging Classifier achieved the best performance (AUPRC = 0.65, AUC = 0.90 (95% CI 0.75–1.00), ACC = 0.85 (95% CI 0.69–1.00), sensitivity = 0.75 (95% CI 0.30–0.95), and specificity = 0.88 (95% CI 0.64–0.97)), and the radiomics signature was composed of 5 selected features. For LNM prediction, the feature selection method minimum redundancy maximum relevance and classifier eXtreme Gradient Boosting achieved the best performance (AUPRC = 0.95, AUC = 0.98 (95% CI 0.94–1.00), ACC = 0.90 (95% CI 0.77–1.00), sensitivity = 0.75 (95% CI 0.30–0.95), and specificity = 0.94 (95% CI 0.72–0.99)), and the radiomics signature was composed of 30 selected features. However, these two chosen models were not significantly different to other models of higher AUC values in DeLong test, though they were significantly different to most of all models.

Conclusion

MRI radiomics analysis based on machine learning demonstrated good predictive accuracies for DD and LNM of ECC. This shed new light on the noninvasive diagnosis of ECC.
Literature
6.
go back to reference Mao Z-y, Guo X-c, Su D, Wang L-j, Zhang T-t, Bai L. Prognostic factors of cholangiocarcinoma after surgical resection: a retrospective study of 293 patients. Medical science monitor: international medical journal of experimental clinical research. 2015;21:2375 https://doi.org/10.12659/MSM.893586.CrossRef Mao Z-y, Guo X-c, Su D, Wang L-j, Zhang T-t, Bai L. Prognostic factors of cholangiocarcinoma after surgical resection: a retrospective study of 293 patients. Medical science monitor: international medical journal of experimental clinical research. 2015;21:2375 https://​doi.​org/​10.​12659/​MSM.​893586.CrossRef
27.
34.
go back to reference Wilcoxon F, Katti S, Wilcox RA. Critical values and probability levels for the Wilcoxon rank sum test and the Wilcoxon signed rank test. American Cyanamid Company Pearl River, NY. 1963:171–6. Wilcoxon F, Katti S, Wilcox RA. Critical values and probability levels for the Wilcoxon rank sum test and the Wilcoxon signed rank test. American Cyanamid Company Pearl River, NY. 1963:171–6.
43.
48.
51.
go back to reference Ciresa M, De Gaetano AM, Pompili M, Saviano A, Infante A, Montagna M, et al. Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. Eur Rev Med Pharmacol Sci. 2015;19(15):2786–97.PubMed Ciresa M, De Gaetano AM, Pompili M, Saviano A, Infante A, Montagna M, et al. Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. Eur Rev Med Pharmacol Sci. 2015;19(15):2786–97.PubMed
61.
go back to reference Tagliaferri L, Budrukkar A, Lenkowicz J, Cambeiro M, Bussu F, Guinot JL, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and skin GEC-ESTRO working group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). Journal of contemporary brachytherapy. 2018;10(3):260. https://doi.org/10.5114/jcb.2018.76982–6.PubMedPubMedCentralCrossRef Tagliaferri L, Budrukkar A, Lenkowicz J, Cambeiro M, Bussu F, Guinot JL, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and skin GEC-ESTRO working group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). Journal of contemporary brachytherapy. 2018;10(3):260. https://​doi.​org/​10.​5114/​jcb.​2018.​76982–6.PubMedPubMedCentralCrossRef
Metadata
Title
Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma
Authors
Yong Tang
Chun Mei Yang
Song Su
Wei Jia Wang
Li Ping Fan
Jian Shu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08947-6

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine